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Abstract
Background: Piroplasmosis caused by the Babesia microti-like piroplasm (Bml) is increasingly being detected in
dogs in Europe. Sick dogs show acute disease with severe anaemia associated with thrombocytopenia with a poor
response to current available drugs. This study assesses the safety and tolerance of three treatments and compares
their efficacy over a full year of follow up in dogs naturally infected with Bml.
Methods: Fifty-nine dogs naturally infected with Bml were randomly assigned to a treatment group: imidocarb
dipropionate (5 mg/kg SC, 2 doses 14 d apart) (IMI); atovaquone (13.3 mg/kg PO q 8 h, 10 d)/azithromycin (10
mg/kg PO q 24 h, 10 d) (ATO); or buparvaquone (5 mg/kg IM, 2 d apart)/azithromycin (same dosage) (BUP).
Before and after treatment (days 15, 45, 90 and 360), all dogs underwent a physical exam, blood tests and parasite
detection (blood cytology and PCR). Clinical efficacy was assessed by grading 24 clinical and 8 clinicopathological
signs from low to high severity.
Results: Before treatment, most dogs had severe regenerative anaemia (88.13%) and thrombocytopenia (71.4%). On
treatment Day 45, clinical signs were mostly reduced in all dogs, and by Day 90, practically all dogs under the ATO
or BUP regimen were clinically healthy (76.4 and 88%, respectively). Highest percentage reductions in laboratory
abnormalities (82.04%) were detected in animals treated with ATO. Over the year, clinical relapse of Bml was
observed in 8 dogs (8/17) treated with IMI. However, on Day 360, these animals had recovered clinically, though
clinicopathological abnormalities were still present in some of them. Parasitaemia was PCR-confirmed on Days 90
and 360 in 47.05 and 50% of dogs treated with ATO, 68 and 60.08% with BUP, and 94.1 and 73.3% with IMI,
respectively. Even after 360 days, 13.3% of the dogs treated with IMI returned a positive blood cytology result.
Conclusions: IMI showed the worse clinical and parasitological, efficacy such that its use to treat Bml infection in
dogs is not recommended. The treatments ATO and BUP showed better efficacy, though they were still incapable
to completely eliminate PCR-proven infection at the recommended dose. All three treatments showed good
tolerance and safety with scarce adverse events observed.
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Background
Canine babesiosis is a serious tick-borne disease caused
by several species of the protozoan genus Babesia [1, 2].
Historically, Babesia infection in dogs was identified
according to the morphological features of the parasite
within the animal’s red blood cells. Based on relative
size, these parasites are broadly divided into two groups,
large and small piroplasms [2]. However, modern mo-
lecular techniques have resulted in the identification of
three genetically distinct small Babesia parasites in dogs:
Babesia gibsoni, Babesia conradae and the Babesia
microti-like isolate. This last species has been recently
reported as “Babesia vulpes” by Baneth et al.[3] and also
described as “Babesia Spanish dog isolate", “Babesia
(Theileria) annae”, or Babesia cf. microti [1].
The Babesia microti-like isolate (Bml) is a small piro-
plasm first described in north-western Spain (as “Babesia
(Theileria) annae” or Babesia cf. microti) where Bml
infection in dogs is now considered endemic [4, 5]. Sick
dogs feature an acute disease with clinical signs such as
pale mucous membranes, anorexia, apathy, fever, haema-
turia, splenomegaly, weight loss, regenerative macrocytic
hypochromic anaemia and thrombocytopenia [5]. Bml
infection is recognized as a serious disease because of its
poor response to current piroplasmosis treatments (imi-
docarb diproiponate) [6].
More recently, the antiprotozoan hydroxynaphtoqui-
none, atovaquone, has proved effective against B. diver-
gens and B. microti infection in cows and humans [7, 8].
In combination with the antibiotic azithromycin, atova-
quone eliminates B. microti parasitaemia in both humans
and hamsters, while neither drug alone eliminates Babesia
parasitaemia [9, 10]. Other piroplasms including B. gib-
soni, B. conradae and Cytauxzoon felis have shown a
response to combined atovaquone/azithromycin treat-
ment [11–13]. This drug combination is the only treat-
ment able to reduce B. gibsoni parasitaemia below the
PCR limit of detection [12], and also seems effective for
the treatment of acute and chronic piroplasmosis caused
by B. conradae [13]. The mechanism of action of atova-
quone against protozoans is through cytochrome b and
electron transport inhibition [14]. The most commonly
used dosing regimen is 13.5 mg/kg of atovaquone admin-
istered orally (PO) every 8 h with fatty food (to maximize
drug absorption) in combination with azithromycin (at a
dose of 10 mg/kg PO) for ten days [1, 12].
The hydroxynaphthoquinone buparvaquone was de-
veloped in the 1980s. Buparvaquone has been exten-
sively tested for veterinary use against bovine theileriosis
[15, 16]. Some authors have also reported the use of
buparvaquone for the treatment of equine piroplasmosis
caused by Babesia equi [17, 18]. Buparvaquone has also
shown activity against other protozoan parasites such
Plasmodium spp. [19], Leishmania spp. [20] or Neospora
spp. [21, 22]. Although the mechanism of action of this
drug has not been fully elucidated, there are indications of
its selective toxicity through inhibition of parasite respira-
tory systems as postulated for Theileria spp., Plasmodium
spp., and Eimeria spp. [19]. Today, buparvaquone is
commercially available for use against theileriosis in cattle
in some African countries.
To date, however, no drug has proved capable of
clearing Bml infection in dogs. Imidocarb dipropionate
remains the first choice treatment against large Babesia
species infection, but when used to treat small species
infection, clinical relapses are very frequents [7]. Not-
withstanding, this drug is often used to treat Bml infec-
tion in dogs in Europe because it is the most accessible
and cheapest treatment available. The present study
compares the efficacy of three anti-Babesia treatments
(imidocarb dipropionate, and the combination treatments
atovaquone/azithromycin and buparvaquone/azithromy-
cin) over a full year of follow up in dogs naturally infected
with Bml. To the best of our knowledge, this is the first




Sixty dogs naturally infected with Bml from seven
veterinary practices in NW Spain (five in Galicia and
two in Asturias) were initially enrolled in this multi-
centre, randomized not blinded trial. Before treatment
(Day 0), all participating dogs were subjected to a
clinical examination and blood collection by cephalic
venipuncture for screening for vector-borne diseases,
complete blood counts (CBC), biochemical tests, and
blood smear and PCR to confirm Bml infection. The
study was carried out in accordance with the Inter-
national Guiding Principles for Biomedical Research
Involving Animals issued by the Council for Inter-
national Organizations of Medical Sciences. Owner
consent was obtained in all cases.
Criteria for inclusion were to present: (i) at least
three clinical signs consistent with canine piroplasmo-
sis: apathy, poor appetite to anorexia, pale mucous
membranes, jaundice, pigmeturia or pigmented faeces
(indicating bilirubin excretion), haematuria and fever;
and (ii) positive blood smear confirmed by nested
PCR and sequencing.
Dogs with Bml infection were excluded if they fulfilled
at least one of the following exclusion criteria: (i) preg-
nant or lactating females; (ii) any vector-borne disease
concomitant infections including B. canis, L. infantum,
E. canis, Anaplasma spp., and Leptospira spp.; (iii)
severe kidney, liver, or heart failure; and (iv) treatment
with antibiotics, antifungals, corticosteroids and/or a
specific anti-Babesia agent within 60 days.
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During the course of the study, dogs were with-
drawn if they met any of the following criteria: (i) use
of different treatment to that assigned; (ii) adverse
events requiring interruption of treatment or follow-
up; and (iii) a secondary infection or illness requiring
a change in treatment.
Screening for vector-borne diseases
Before enrollment, blood samples were collected from
each dog to screen for the most prevalent companion
vector-borne diseases (CVBD) in Spain [23] by different
techniques: other Babesia species (PCR and sequencing)
[23], Leishmania infantum and Ehrlichia canis (immu-
nofluoresent antibody test, in-house), Anaplasma spp.
and Leptospira spp. (SNAP® 4DX; SNAP® Lepto Test
-IDEXX Laboratories).
Treatment groups
Each dog was randomly assigned to a treatment group:
17 dogs were treated with imidocarb dipropionate
(5 mg/kg SC twice 15 days apart) (IMI group); 17 dogs
were treated with atovaquone (13.5 mg/kg PO TID/
10 days) plus azithromycin (10 mg/kg PO SID/10 d)
always administrated with fatty food (ATO group); and
26 dogs were treated with buparvaquone (5 mg/kg IM
twice 48 h apart) plus azithromycin (10 mg/kg PO
SID/10 d) (BUP group). All included dogs were treated
with acaricides against ticks throughout the study on a
regular basis.
If, during the study, a dog showed clinical relapse
despite treatment indicated by parasitaemia (blood smear)
and/or PCR, the animal was subjected to the same treat-
ment protocol as before.
Atovaquone and azithromycin were used out of label
since these were not available for veterinary use in Spain
at the time of our study. Buparvaquone was imported
from Egypt (under authorization by the Spanish Medica-
tion and Medical Products Agency) where it is licensed
to treat bovine theileriosis.
Sample collection
All dogs underwent a thorough physical exam, blood
counts and biochemical profiling along with parasite
detection after treatment (Days 15, 45, 90 and 360).
From each dog, a 4.5 ml blood sample was obtained
by cephalic venipuncture and 1.5 ml of the collected
blood placed in two EDTA tubes: a 1 ml tube for
CBC and blood smears and a 0.5 ml tube for Bml de-
tection by genomic DNA isolation and nested PCR.
The remaining 3 ml of blood were placed in tubes
without anticoagulant for biochemical profiles and




Each dog was scored by the same veterinarian before (Day
0) and after treatment (Days 15, 45, 90 and 360) for 23 clin-
ical signs using a categorized scoring system from 0 to 3
(from low to high severity) to obtain an over-all clinical
score (maximum score of 63) (Table 1 adapted from Miró
et al. [24]). The clinical response to treatment was assessed
by examining changes produced in clinical scores over time
as score percentage reductions (PR) calculated as described
by Hernández et al. [25].
Clinicopathological signs
Dogs were also scored for 8 clinicopathological abnor-
malities (CBC and biochemical profile) using a catego-
rized scoring system from 0 to 2 (maximum score of 12)
(Table 2). Percentage reductions in scores over time
were also calculated. Complete blood counts included
leukocyte count, red blood cell count (RBC), haemoglo-
bin concentration, haematocrit, red cell distribution
width (RDW), mean corpuscular volume (MCV), mean
corpuscular haemoglobin (MCH), mean corpuscular
haemoglobin concentration (MCHC) and platelet count.
Biochemical profiles included total serum protein, urea,
creatinine, aspartate aminotransferase (AST), alanine
aminotransferase (ALT) and symmetric dimethylarginine
(SDMA) (only determined in 9 dogs due to the recent
availability of this test on the market).
Parasitological follow up
Blood cytology
Thin blood smears were examined by light microscopy
(LM) to detect intraerythrocytic forms consistent with
small Babesia merozoites. The smears were air-dried,
fixed in absolute methanol for 5 min, stained using 20%
Giemsa and then microscopically examined using a
1000× magnification objective under immersion oil. The
level of parasitaemia was subjectively defined as low,
moderate or high [10]. All smears were examined by the
same technician.
DNA isolation, nested PCR and sequencing
Genomic DNA was isolated from peripheral whole
blood (200 μl) before (Day 0) and after treatment
(Days 90 and 360) using the QIAamp® DNA blood
mini kit (Qiagen, Barcelona, Spain) following the man-
ufacturer’s instructions. The extracted DNA was eluted
in sterilized water (200 μl) and stored at -20 °C until
further use.
On Days 0, 90 and 360, blood DNA was detected by
nested amplification of the 18S rRNA gene fragment.
On Day 0 Blood-DNA was screened for piroplasms
using PCR assays including a shorter nested PCR
(850 bp; primers BT F1/R1 followed by BT F2/R2) [26].
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PCR products corresponding to the expected length
were purified (15 μl) using a QIAquick Purification Kit
(Qiagen) as described by the manufacturer and se-
quenced at the Genomic sequencing service (UCM)
using an ABI Prism 3730 (Applied Biosystems).
Sequence chromatogram files were analyzed by Chromas
2.1.1, and imported into BioEdit v7.0.5, for editing, assem-
bly and alignments. The sequences obtained during the
present study were aligned to sequences available from
GenBank using Clustal W and compared whit the
Table 1 Score system used to grade 23 clinical signs in dogs with Bml infection (maximum score = 63)
Condition and
affected organ
Clinical sign Severity grade
0 1 2 3
General Appetite Normal Reduced Anorexia
Asthenia Absence Reduced Mild Prostration
Fever (≥ 39.5 °C) Absence 39.5–40 °C > 40
Polyuria/Polydipsia Absence Drinks less than
twice normal amount
Drinks from 2 to 4
times normal amount
Drinks more than 4
times normal amount
Body condition Weight loss Absence Reduced (< 10%) Mild (10–20%) Severe (> 20%)
Mononuclear
phagocyte system





Splenomegaly Absence – Presence –
Hepatomegaly Absence – Presence –
Mucosae Pale mucous membranes Absence Light (membranes pale) Mild Severe (membranes white)
Jaundice Absence Light Mild Severe (yellow
mucous membranes)
Epixtasis Absence Occasional Frequent Permanent
Haematuria Absence Light Mild Severe
Dark urine (bilirubin excretion) Absence Light Mild Severe (dark urine)
Vomiting Absence Occasional Frequent Haematemesis
Diarrhoea Absence Occasional Frequent Haematochezia
Melena Absence Occasional Frequent
Constipation Absence Occasional Frequent Severe tenesmus
Faeces Normal Dark (bilirubin excretion)
Musculo-skeletal system Limp Absence Light Moderate Severe
Cardiac and
respiratory System
Tachycardia Absence – Presence –
Tachypnea Absence – Presence –




≥ 25% of body surface
Equimosis Absence ≤ 10% of
body surface
10–25% of body surface ≥ 25% of body surface
Table 2 Score system used to grade clinicopathological abnormalities in dogs with Bml infection (maximum sore = 12)
Variable Severity grade
0 1 2
CBC Haematocrit/haemoglobin Normal Regenerative Non regenerative
Leukocytes Normal Leukocytosis Leukopenia
Platelets Normal ̶ Thrombocytopenia
Biochemical profile Total serum protein Normal Proteinaemia Hypoproteinaemia
Urea Normal Elevated –
Creatinine Normal Elevated –
ALT Normal Elevated –
AST Normal Elevated –
Checa et al. Parasites & Vectors  (2017) 10:145 Page 4 of 12
additional piroplasms sequences available from GenBank
using BLAST program (https://blast.ncbi.nlm.nih.gov/
Blast.cgi) to determinate percentage identity of the
generated sequences against published sequences.
The nested PCR procedure used during follow-up has
been recently validated for the detection of Bml by
nested amplification of the 18S rRNA gene fragment
using the universal Babesia-Theileria primers BT1-F (5'-
GGT TGA TCC TGC CAG TAG T-3') and BTH-1R (5'-
TTG CGA CCA TAC TCC CCC CA-3') [27] for
primary, and the B. microti-like isolate specific primers
BTFox1F (5'-AGT TAT AAG CTT TTA TAC AGC-3')
and BTFox1R (5'-CAC TCT AGT TTT CTC AAA GTA
AAA TA-3') for the second amplification round obtained
a fragment of 655 bp [28].
The reaction mixture (adapted from Bartley et al. [28])
and amplification conditions were as follows: 2 μl of
extracted DNA was added to a 23 μl volume of reaction
mixture containing 0.75 units of Tth Plus DNA polymer-
ase 5U/μl (Biotools B&M Labs., Madrid, Spain), 200 μM
(each) deoxyribonucleotides (dATP, dTTP, dGTP, dCTP)
(Biotools B&M Labs), 10 pmol of each primer (Thermo
Fisher Scientific, Paisley, Scotland), 2.5 μl 10× PCR buffer
and 1.5 mM MgCl2 (Biotools B&M Labs). Negative (2 μl
dH2O) and positive (the B. microti-like isolate DNA)
control samples were included in each PCR assay.
PCR products were run on a 1.5% agarose gel con-
taining SYBR Safe Gel Stain (Invitrogen, USA), and
visualized with a dark reader trans-illuminator (Clare
Chemical, USA).
Statistical analysis
Results were analyzed using the statistics package SAS
version 9.4. Each treatment group was independently
compared with the other two. Mean differences in out-
come variables between the different days post-treatment
were compared by repeated measures ANOVA. This
model included group, time-point, and the interaction
time by treatment as fixed effects, and subjects (dogs) as
the random effect. Since the effect of time by treatment
was found globally significant in the ANOVA, the non-
parametric Kruskal-Wallis test was used to compare
groups at each time point. Since the Kruskal-Wallis test
was significant in each group, post-hoc pairwise Wilcoxon
signed rank tests were performed to establish differences
between groups between time-points. For categorical
variables, the Chi-square test was used. Significance
was set at P ≤ 0.05.
Results
Of the 60 dogs initially enrolled, one dog treated with
buparvaquone/azithromycin (BUP) suffered clinical re-
lapse with azotaemia on Day 90. Despite further treat-
ment with atovaquone/azithromycin (ATO), this dog
died due to renal failure. Of the final study population of
59 dogs, several dogs were lost to follow up during the
course of the study: eight on D15 (6 in IMI, 2 in BUP),
seven on D45 (3 IMI, 3 BUP, 1 ATO) and eight on D360
(2 IMI, 3 BUP, 3 ATO). In all but one case, the reason
for these losses was that owners failed to return for the
re-visits. One of the dogs lost to follow up on D360 was
run over by a car.
All included dogs were positive by nested PCR and
sequenced on Day 0. When we compared our 60 sequen-
cing results with existing GenBank entries, the sequences
obtained were identified as B. microti-like isolate in
BLAST searches. All the sequences obtained were 99–
100% identical to several isolates of “Babesia annae” (“Ba-
besia annae”, “Theileria annae”, “Theileria annae isolate
Dog#8”, accession numbers KT580785, JX679165 and
JX454779, respectively). No other Babesia species were
identified in the dog blood samples.
Comparison of treatment groups at baseline
Of the 59 participating dogs with Bml, 29 were female and
30 male; mean age was 3.23 years (95% CI: 2.54–3.91);
mean body weight was 16.58 kg (95% CI: 13.99–19.17)
and 39 were hunting dogs and 20 companion dogs. Ani-
mal distributions across the three treatment groups were
homogenous and there were no significant differences in
relation to sex (χ2 = 1.082, df = 2, P = 0.58), lifestyle (χ2 =
1.267, df = 2, P = 0.53) or age (F(2,53) = 2.840, P = 0.06)
among the three groups (Tables 3 and 4).
Clinical efficacy
Before treatment, mean body temperature was 38.94 °C
(95% CI: 38.75–39.13) with a minimum of 36.5 °C and a
maximum of 40.6 °C recorded. The most prevalent
clinical signs observed in the physical examination were
anorexia (86.4%), pale mucous membranes (84.7%), ap-
athy (81.3%) and weariness (89.8%). Other reported
clinical signs may be observed in Fig. 1.
On Day 15, 16/51 (31.4%) of dogs showed pale mu-
cous membranes (8 of which were treated with IMI), 9/
51 showed asthenia and 6/51 showed loss of appetite.
The dogs showing worse clinical progression on Day 15
were those treated with IMI. On Day 45, pale mucous
membranes were observed in eight dogs out of 17 (6 of
which were treated with IMI), weariness in 5, apathy in
Table 3 Baseline data (D0) recorded in dogs of the three
treatment groups. Categorical variables
Variable ATO BUP IMI P-value
Sex (n) Female 10 12 7 0.58
Male 7 13 10
Lifestyle (n) Hunting 13 16 10 0.53
Companion 4 9 7
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3 and appetite loss in 3. On Day 90, four dogs still had
pale mucous membranes (Fig. 2).
No significant differences in scores were observed be-
tween different treatment groups (F(2,39) = 0.179, P = 0.14).
However, on Days 15, 45 and 90, clinical signs were
reduced in greater measure in the groups ATO and
BUP compared with IMI (Fig. 3a). After one year of
follow up, all dogs showed a normal clinical status
with the exception of one dog treated with ATO
which presented with pale mucous membranes, weari-
ness and apathy.
Clinicopathological abnormalities
The main haematological finding before treatment was
anaemia (93.22%; 55/59); in most of the dogs anaemia
was regenerative (88.13%; 52/59) and in 5% (3/59) it was
non-regenerative. Besides regenerative, anaemia was
most often hypochromic and macrocytic. The second
most prevalent finding was thrombocytopenia (71.4%;
30/42). Leukocyte counts were elevated in 27.1% (16/59)
(mostly neutrophilia) and diminished in 2 dogs.
Biochemical abnormalities detected before treatment
were elevated total serum proteins (17.5%; 10/57) and
Table 4 Baseline data (D0) recorded in dogs of the three treatment groups. Continuous variables
Variable Treatment group Dogs (n) Mean ± SD 95% CI Min-Max P-value
Age (years) ATO 17 4.26 ± 2.56 2.94–5.58 0.25–9 0.06
BUP 24 3.16 ± 2.71 2.01–4.30 0.16–10
IMI 15 2.17 ± 1.94 1.09–3.24 0.25–6
Body weight (kg) ATO 17 15.23 ± 9.80 10.28–20.37 6.50–36 0.78
BUP 25 16.67 ± 10.34 12.40–20.90 2.40–52
IMI 17 17.72 ± 9.88 12.60–22.80 5.3–40
Temperature (°C) ATO 17 38.70 ± 0.84 38.20–39.13 36.5–40.2 0.2
BUP 25 39.00 ± 0.74 38.70–39.30 37–40.6
IMI 17 39.10 ± 0.60 38.70–39.40 38–40
Clinical score D0 ATO 17 13.00 ± 7.82 8.90–17.02 3–27 0.85
Clinical signs (points) BUP 25 12.40 ± 6.20 9.80–14.90 3–27
IMI 17 11.76 ± 5.17 9.10–14.42 7–24
Clinical score D0 ATO 17 3.23 ± 1.70 2.30–4.15 1–7 0.4
Clinicopathological abnormalities (points) BUP 25 2.70 ± 1.30 2.16–3.27 1–5
IMI 17 2.70 ± 0.83 2.33–3.19 1–4
Abbreviation: SD Standard deviation
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Fig. 1 Percentage clinical signs observed on D0
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elevated hepatic enzyme activity (ALT) (10.7%; 6/56).
Azotaemia was observed in 1.75% of cases (1/57) and
elevated blood urea levels in 12.5% of the cases (7/56).
Following treatment, all three groups showed the
similar behaviour of blood panel results. Red blood cell
counts and haematocrits increased between each of the
follow-up times (Greenhouse-Geisser, G-G = 99.6, df = 3.43,
P ≤ 0.001; G-G = 104.7, df = 3.17, P ≤ 0.001; respectively)
(Fig. 4a). A significant decrease was produced in MCV
from Day 15 to Day 45 (Greenhouse-Geisser, G-G =
4.086, df = 3.12, P = 0.008) and values thereafter stabi-
lized within the normality range (60–76 fl). Differences
among the three groups in these three variables were
not significant. Platelets counting were normalized on
Day 15 in the ATO and BUP; and on D45 in the IMI
group (Fig. 4b)
Leukocyte counts also behaved similarly over time in
the three groups with significant reductions observed
(Greenhouse-Geisser, G-G = 7.205, df = 2.764, P ≤ 0.001)
from Day 0 to Day 15. Neutrophil counts also fell over
time in the three treatment groups.
Total serum protein and creatinine levels also showed
similar behaviour in the three groups with significant in-
creases produced in the means of both variables relative
to Day 0 for each time point (Greenhouse-Geisser, G-G
= 5.3, df = 3.141, P = 0.02 and G-G = 19.609, df = 3.357,
P ≤ 0.001, respectively).
At one year of follow up, 5.7% dogs had azotaemia (3/
52) (Fig. 5a) and 12.7% elevated blood urea levels (6/47)
(Fig. 5b) and elevated total serum protein levels were
recorded in 29.4% of the dogs (15/51). The last nine
dogs enrolled were also subjected to the SDMA kid-
ney function test (7 in ATO, 2 in BUP). Of these 9
animals, 5 showed elevated SMDA levels on Day 90
(up to 14 μg/dl). However, only two of these five dogs
(including the dog with high creatinine on Day 90)
continued to show high SMDA levels (15 and 18 μg/
dl) on Day 360.
The worst percentage reductions in clinicopathological
abnormalities, between time points, were recorded in
the dogs treated with IMI. On Day 15, dogs included in
IMI group only showed a 25.4% reduction compared to
54.4 and 44.11% obtained in the ATO and BUP groups,
respectively. Highest percentage reductions in laboratory
abnormalities (82.3%) were observed on Day 360 in dogs
treated with ATO (Fig. 3b).
Blood smears
Following treatment, the IMI group showed the largest
number of dogs with blood smears testing positive for
Bml infection (Fig. 6a). On Day 15, significant differ-
ences between groups were produced, whereby 9/11
dogs in IMI and 5/23 dogs in BUP showed positive blood
smears versus no dogs in the ATO group (IMI vs ATO: Z
= 20.86, P ≤ 0.001; IMI vs BUP: Z = -15.32, P = 0.001).
Even by Day 45, more than half of the dogs in the IMI
group tested positive (57.14%), while 18.7 and 27.27%
were positive in ATO and BUP, respectively. On Day 90,



































Fig. 2 Number of dogs with clinical signs recorded during follow up. a Atovaquone treatment group (ATO). b Buparvaquone treatment group
(BUP) c Imidocarb dipropionate treatment group (IMI)
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significant differences in positive blood smears emerged
between IMI and BUP (Z = -10.34, P = 0.028), the IMI
group showing the highest percentage of dogs testing
positive (47%) in comparison with the BUP group
(12%). However, differences between ATO and BUP
were not produced at this time point (Fig. 6a). After
one year of treatment, 1/14 dog in ATO, 2/23 dogs
in BUP and 2/15 dogs in IMI returned borderline
positive blood smear results.
Specific nested PCR
Significant differences in changes in PCR parasitaemia
rates over time (Day 0 vs Day 90 and Day 360) were de-
tected in the three groups (Greenhouse-Geisser, G-G =
18.266, df = 1.967, P < 0.001). After three months and 1
year of treatment, respectively, parasitaemia was PCR-
confirmed in 47.05% (8/17) and 50% (7/14) of dogs
treated with ATO, 68% (17/25) and 60.8% (14/23) of
those treated with BUP and 94.11% (16/17) and 73.3%
(11/15) of those treated with IMI (Fig. 6b). These differ-
ences between the three groups were not however sig-
nificant (F(2,49) = 2.057, P = 0.139).
Safety and tolerance
No negative impacts on haematology or biochemistry vari-
ables (notably on renal or hepatic biomarkers) were re-
corded throughout the trial in the three treatment groups.
In dogs in IMI, atropine (0.02 mg/kg SC) was used to avoid
product-related cholinergic effects and there was pain upon
injection on 26.6% of the cases, and 23.5% of dogs in the
ATO group experienced vomiting lasting for 2–3 days after
starting treatment, and omeprazol (0.5 mg /kg PO SID/10
d) given in those cases. The buparvaquone/azithromycin
combination was well tolerated in all dogs and no product-
related adverse events were reported.
Relapses
We recorded 8/17 Bml-positive dogs by blood smear
on Day 45 in the IMI group. These eight dogs
showed clinical relapse indicated by a clinical score of
1 to 7 points. Six of these dogs presented with regen-
erative anaemia (mean 4.42 × 106 cells/μl and haem-
atocrit 36%) and two with thrombocytopenia. All
were retreated with imidocarb dipropionate (one dose
5.5 mg/kg IM) at this time point.











































Fig. 3 Percentage reductions recorded in clinical signs a and clinicopathological abnormalities b after treatment. *Asterisks indicate dogs showing a
clinical relapse: 8 dogs on D45 in the IMI group, 2 dogs on D90 in the BUP group, and 3 dogs on D90 and 1 dog on D360 in the ATO group
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Further dogs returning positive blood smears (3/25 in
BUP and 3/17 in ATO on Day 90) showed clinical re-
lapse: two dogs in BUP and three in ATO consisting of
mild regenerative anaemia and clinical scores of 0 to 6
points. These six dogs were retreated with BUP or ATO
at this time point.
Discussion
Among many different babesicides used in veterinary
medicine, imidocarb dipropionate and diminazene
aceturate are the most widely used in cows and horses,
while the former is the first choice of treatment for
canine babesiosis caused by large Babesia species. In
addition, the combination atovaquone/azithromycin has
proved successful against some Babesia spp. that infect
humans, particularly Babesia microti and Babesia diver-
gens [7]. Several other piroplasms, including B. gibsoni,
B. conradae and Cytauxzoon felis [11–13], respond to
combined atovaquone/azithromycin treatment. In con-
trast, buparvaquone has been extensively tested for
veterinary use against theileriosis in cattle [16] and
babesiosis in horses [18], but there are no reports of its
application in dogs and/or cats.
The present clinical trial was designed to compare the
efficacy of three treatments (imidocarb dipropionate,
IMI, atovacuone plus azithromycin, ATO and buparva-
quone plus azithromycin, BUP) in an effort to improve
the current clinical management of canine piroplasmosis
caused by Bml. To our knowledge, this study is the first
Fig. 4 Haematocrit a and platelets counts b follow-up in treated
dogs. The red lines indicate the reference values, i.e. 37% haemato-
crit a and 200 × 103/μl platelets b
Fig. 5 Creatinine a and urea b follow-up in treated dogs. The red lines
indicate the reference values, i.e. 1.4 mg/dl creatinine a and 58 mg/dl
urea b
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to compare the use of BUP against this small piroplasm
in naturally infected dogs with that of ATO or IMI.
Out of 60 dogs included in our trial, 77.9% responded
well to treatment in terms of clinical improvement while
22% dogs showed clinical relapse. Clinical signs present in
several dogs at the time of inclusion were reduced in fre-
quency and severity in response to treatment. These signs
were: asthenia, decreased appetite, pale mucous mem-
branes, fever, orangey faeces, pigmenturia, tachycardia,
splenomegaly, haematuria, tachypnea and jaundice. Simi-
lar clinical signs have been reported in infected dogs with
Bml in Spain [5, 29]. Overall, the disease course showed
clinical improvement in response to treatment. Dogs
showing the worst clinical progression on Days 15, 45 and
90 following treatment were those treated with IMI.
Similarly, main haematological abnormalities showed a
general trend towards their reduced frequency and severity,
including regenerative anaemia and thrombocytopenia,
consistent with prior reports [5, 6]. Total leukocyte counts
(mainly neutrophiles) also showed a decreasing tendency.
Leukocyte disorders have been inconsistently observed in
dogs with piroplasmosis [29]. This could be a consequence
of the severe stress associated with this illness, in line with
observations by other authors [5, 6].
In contrast, other clinicopathological alterations, such
as total serum protein and creatinine levels remained
elevated throughout the whole year of follow up. Thus,
we recorded azotaemia rates of 1.7 and 5.7% at the start
and end of follow up, respectively, and one dog died of
kidney failure. Others have observed higher prevalence
of kidney disease (36%) [6] in Bml infected dogs and
suggested its strong correlation with likelihood of death
within the first week of diagnosis [30]. In our study, the
dogs that showed azotaemia at the start and end of
follow up were not the same ones. Hence, azotaemia ob-
served in dogs at the time of treatment (1.7%) responded
well to treatment while 5.7% dogs, all of them hunting
dogs, developed azotaemia after treatment. These latter
animals may have developed immunomediated glom-

































Fig. 6 Percentages of dogs testing positive for the Babesia microti-like piroplasm infection dogs by blood smear a or PCR b before and after
treatment. Asterisks indicate a significantly higher parasitaemia level in the IMI group versus ATO (P ≤ 0.001 on D15) and versus BUP (P = 0.001
on D15; P = 0.028 on D90)
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complex deposition. In a dog infected with B. gibsoni,
Slode et al. (2011) reported membranoproliferative
glomerulonephritis due to immune complex deposition
[31]. However, it should be noted that most of the dogs in
our study with Bml were hunting dogs [5, 29]. Thus,
chronic kidney disease in these animals could be more
associated with their poor management (including many
hours without drinking while hunting over several days)
than a proper consequence of Bml infection. There were
some dogs with increased urea levels without azotaemia, it
could be due to high protein food, hipertermia, and/or
early prerenal azotaemia (shock, dehydration). More stud-
ies are needed using urine biomarkers of renal function
from the early course of the infection to improve know-
ledge of the renal impacts of Bml infection in dogs.
Our study showed good correlation between LM and
PCR on Day 0 (100% positive dogs, both methods),
because all blood smears were observed by the same
qualified technician. It should also be noted that we
assume that most of the dogs examined in this study
were in the clinical phase of Bml infection time-point
when the visual detection of piroplasms is easier, than in
animals with low parasitaemia levels due to chronic
disease [5]. However, during the follow up (Day 90 and
360), PCR detected more positive dogs than LM in the
three groups. In effect, LM has been described as less
sensitive than PCR to detect chronic and subclinical
piroplasmosis in carrier dogs [5, 32].
Generally, worse improvements in clinicopathological
abnormalities at each time point (especially the first
45 days) were observed in the dogs treated with imido-
carb dipropionate. Although this drug is the treatment
of choice for canine babesiosis caused by large piroplasm
species, in clinical cases caused by small Babesia species
it seems incapable of completely eliminating parasites
from the bloodstream at the recommended dose, only
improving the severity of clinical signs [7]. Our study
shows that IMI reduces parasitemia (both by blood
smear and PCR) to a lesser extent than atovaquone or
buparvaquone plus azithromycin, such that relapse was
frequently seen and most dogs remained subclinically
infected when treated with IMI. Treatment with ATO
gave rise to better results in terms of clinical signs, cli-
nicopathological abnormalities and parasitaemia. These
results were similar to those obtained for BUP.
Atovaquone plus azithromycin has been used to
treat small piroplasms such as B. conradae and B.
gibsoni [12, 13]. None of twelve clinical cases of B.
conradae treated with atovaquone plus azithromycin
showed detectable B. conradae DNA by PCR at any
time-point after treatment ended (Day 120) [13]. Similarly,
B. gibsoni (Asian genotype) DNA was detectable by PCR
in posttreatment samples in 2/10 treated dogs: one dog
tested positive at 60 and 90 days post-treatment, and the
other dog tested positive 90 days after treatment [12]. In
the present study, the number of treated dogs was larger
and follow up was longer than 120 days. On Day 15, Bml
was not detected in blood smears but from Days 45 to
360, positive results were obtained, both by PCR and
blood smear. The detection of dogs positive for the para-
site after treatment indicates treatment failure, reinfection,
or lack of adherence to treatment. The resistance of other
protozoa to atovaquone has been associated with muta-
tions in the cytochrome b gene [9, 33].
Buparvaquone plus azithromycin given at a dose of
5 mg/kg IM and a second dose 48 h later proved safe and
was better tolerated than the other two treatment regimens.
Some dogs treated with ATO experienced vomiting for two
or three days after starting treatment. All dogs treated with
IMI were first given atropine to avoid cholinergic effects.
We observed a better clinical and parasitological efficacy of
BUP than IMI suggesting buparvaquone could be an inter-
esting new approach to treating small piroplasm infections
in dogs. In effect, other authors have shown that buparva-
quone, in combination with other drugs, could be a better
choice than imidocarb against B. equi infection [18], though
further clinical trials are required in horses.
While atovaquone monotherapy is not recommended
for the treatment of human babesiosis caused by B.
microti, its combination with azithromycin has proved
effective in experimental animals and humans [9, 10].
Hence, it would be interesting to test the use of buparva-
quone or atovaquone alone to treat Bml. This approach
would limit the use of macrolides in animals and thus also
helps minimize antibiotic resistance in humans.
So far, no specific safe and efficient treatment for piro-
plasmosis exists and the majority of dogs treated with
specific antibabesial drugs are unlikely to be cured of their
infection. Any dog with confirmed Bml infection should
be regarded as potentially infected for life, despite specific
treatment and remission of clinical signs [2]. The epi-
demiological role of dogs that continue subclinically in-
fected after treatment remains unclear. Further clinical
trials are needed to improve the clinical management of
canine piroplasmosis in the small animal practice.
Conclusions
Of the three treatments tested, imidocarb dipropionate
showed the worse clinical and parasitological efficacy
against B. microti-like piroplasm infection in dogs. We
would therefore not recommend its use for this purpose.
The combination atovaquone/buparvaquone plus azi-
thromycin showed the best clinical and parasitological
efficacy, though it was still incapable of completely
eliminating the infection at the recommended dose. All
three treatment regimens were well tolerated and safe
and buparvaquone/azithromycin protocol was the only
one not showing any adverse events in treated dogs.
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